Does addition of 6 months' androgen suppression to radiotherapy prolong survival of men with prostate cancer?

被引：0

作者：

Eric M Horwitz

机构：

[1] Clinical Director and Associate Professor in the Department of Radiation Oncology at Fox Chase Cancer Center,

来源：

Nature Clinical Practice Urology | 2005年 / 2卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：16 / 17

页数：1

共 50 条

[1] Does addition of 6 months' androgen suppression to radiotherapy prolong survival of men with prostate cancer?
Horwitz, EM
NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (01): : 16 - 17
[2] Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
Pollack, A
Horwitz, EM
NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (01): : 12 - 13
[3] Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
Alan Pollack
Eric M Horwitz
Nature Clinical Practice Oncology, 2005, 2 : 12 - 13
[4] Does the addition of vinorelbine to hormone therapy prolong survival of men with hormone-refractory prostate cancer?
Karl Pummer
Nature Clinical Practice Urology, 2005, 2 : 80 - 81
[5] Does the addition of vinorelbine to hormone therapy prolong survival of men with hormone-refractory prostate cancer?
Pummer, K
NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (02): : 80 - 81
[6] Primary androgen deprivation therapy does not prolong survival in most patients with prostate cancer
不详
FORMULARY, 2008, 43 (09) : 341 - 341
[7] Does the Addition of Brachytherapy And/or Androgen Deprivation Therapy to External Beam Radiotherapy Correlate with Improved Survival in Men with Unfavorable Intermediate-risk Prostate Cancer?
Andruska, Neal
Agabalogun, Temitope
Fischer-Valuck, Benjamin
Brenneman, Randall
Huang, Yi
Gay, Hiram
Michalski, Jeff
Carmona, Ruben
Baumann, Brian
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : S59 - S60
[8] Improved survival of men with metastatic prostate cancer treated with androgen deprivation therapy plus radiotherapy to the prostate
Yano, Akihiro
Kagawa, Makoto
Takeshita, Hideki
Okada, Yohei
Morozumi, Makoto
Kawakami, Satoru
INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 (12) : 863 - 865
[9] Greater than 6 months of androgen deprivation therapy does not improve overall survival for high-risk prostate cancer patients treated with radiotherapy or prostatectomy
Robinson, C.
Reddy, C.
Klein, E.
Kupelian, P.
Angermeier, K.
Ulchaker, J.
Ciezki, J. P.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S378 - S378
[10] Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Sternberg, CN
NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (01): : 20 - 21

← 1 2 3 4 5 →